Skip to main content

Table 3 Clinical information of patients who were unheard follow upinpublic health facilities of Addis Ababa, during 2007-June 2012

From: Effectiveness of isoniazid preventative therapy in reducing incidence of active tuberculosis among people living with HIV/AIDS in public health facilities of Addis Ababa, Ethiopia: a historical cohort study

Clinical information when ART initiated (N = 2046) IPT exposed
N (%)
IPT Non-exposed
N (%)
N (%) Chi-square
P value
WHO stage of HIV/AIDS
 Stage 1 151(16.02) 138(12.5) 289(14.1) 0.000
 Stage 2 367(39) 294(26.6) 661(32.3)  
 Stage 3 394 (41.8) 551(49.9) 945(46.2)  
 Stage 4 30 (3.18) 121(11.0) 151(7.4)  
CD4cells count/μl(mean = 151.2, SD = 84.9)
 ≤200 537 (37.9) 1020(92.4) 1557(76.1) 0.000
 >200 263 (27.9) 226(20.5) 489(23.9)  
Weight in Kg (mean = 53.2, SD = 9.5)
 <50 241(25.6) 506(45.8) 747(36.5) 0.011
 50–59 479(44.2) 366(33.1) 845(41.3)  
 60–69 164 (17.4) 164(14.9) 328(16.0)  
 >69 58 (6.2) 68(6.2) 126(6.2)  
TB screened
 Yes 942(100) 1100(99.6) 2042(99.8) 0.64
 No 0 4(0.4) 4(0.2)  
CPT adherence
 Good 791(84) 1096(99.3) 2032(99.6) 0.046
 Fair 3(.32) 6(0.5) 9(0.3)  
 Poor 3(.32) 2(0.2) 5(0.2)  
ART adherence
 Good 937(99.5) 1100(99.6) 2037(99.6) 0.124
 Fair 5(0.53) 2(0.2) 7(0.3)  
 Poor 0 2(0.2) 2(0.1)  
OIs after ART initiated
 None 937(99.5) 1052(95.3) 1989(97.21) 0.000
 Fungal 3(.32) 20(1.8) 23(1.12)  
 Viral 0 12(1.0) 12(0.5)  
 Bacterial 0 12(1.0) 14(0.7)  
 Bacterial & fungal 0 4(0.4) 4(0.2)  
 Othersa 0 4(0.4) 4(0.2)  
  1. aProtozoal, viral & bacterial & fungal & viral infections